PubMed Health⌕ Search

Biomedical subjects

F Fraschini

Publications and source records attributed to F Fraschini.

At least 145 records · Page 8Linked to original sources
PubMed1985

Penetration of erythromycin into tonsillar tissue.

A study was carried out to investigate serum levels and tonsillar tissue penetration of erythromycin in 80 children suffering from chronic tonsillitis who had to undergo tonsillectomy. Oral erythromycin ethyl succinate (1 g twice daily) was given for the 2 days preceding surgery, the last dose scheduled for 2, 3, 4 or 6 hours before the start of the operation and the withdrawal of blood and tissue samples. The results showed that erythromycin penetrated quickly into tonsillar tissue and the levels were higher in tissue than in serum at all time points. Mean levels of erythromycin were consistently greater than the minimum inhibitory concentrations for most common Gram-positive oro-pharyngeal pathogens and H. influenzae.

Administration, Oral↗
PubMed1985

Relative bioavailability in humans for oral tablets and solutions of lormetazepam.

A study was carried out to estimate the relative bioavailability of 7-chloro-5-(2-chlorophenyl)-3-hydroxy-1-methyl-1, 3-dihydro-1H-1,4-benzodiazepine-2-one (lormetazepam, Minias) in humans after administration of oral tablets and solutions. Plasma concentration of the drug was measured by gaschromatography with electron capture detector. Six healthy males were each given both formulations. With the oral solution higher plasma peak concentration and a shorter peak time were observed than with tablets. Also the elimination half-life was shorter with the oral solution, while no difference was found with the AUC.

Administration, Oral↗
PubMed1985

Flumethasone pivalate (Locorten) in the treatment of oral diseases.

The combination flumethasone pivalate + iodochlorohydroxychinoline drops was used in 40 patients, 24 males and 16 females, mean age 42.6 years, suffering from infectious enanthema (35%), periodontitis (30%), aphthous stomatitis (25%) and abscess due to prosthesis (10%). After application of 2-3 drops of the combination t.i.d. for 2-7 days, satisfactory results were obtained in all the patients. Tolerance was good; mild unwanted effects occurred in 2 patients (5.0%). Thus the combination flumethasone pivalate + iodochlorohydroxychinoline appears to be very effective in the treatment of oral diseases because its action is more rapid and stronger than that of other currently used drugs.

Abscess↗
PubMed1985

Comparative study on the electrophysiological responses at thalamic level to different analgesic peptides.

Using electrophysiological methods to detect the extracellular activity of single neurons in the thalamus of anaesthetized rats, their response to mechanical and thermal noxious stimuli were assessed before and after administration of 4 analgesic peptides of various types. Dermophin, a peptide extracted from frog's skin, was found to have an opioid-like antinociceptive activity antagonized by naloxone. Caerulein, which has a similar origin, failed to suppress the nociceptive responses of thalamic neurons evoked by peripheral stimuli. Calcitonin, a peptide found at brain level, induced an alteration of the increased firing characteristic of noxious stimuli, and its action was not reversed by naloxone. FK 33-824, a synthetic peptide, induced a morphine-like action when injected i.c.v. at a dosage 1000 times lower than that of morphine on a molar basis. It is concluded that electrophysiological investigations on peptides endowed with analgesic activity contribute greatly to a more precise profile of the peptides as candidate drugs in pain control.

Analgesics↗
PubMed1985

Comparison between penetration of amoxicillin combined with carbocysteine and amoxicillin alone in pathological bronchial secretions and pulmonary tissue.

Patients with chronic bronchitis were treated orally with either amoxicillin (500 mg) alone or in combination with carbocysteine (150 mg), thrice daily for five days, in order to assess whether the combination allows higher antibiotic levels to be obtained in bronchial mucus than those obtained from amoxicillin alone. Serum and mucus levels were determined for each patient at first and fifth day of the two drug regimens. The levels of amoxicillin in the lung tissue collected in patients undergoing pulmonary surgery were also determined after a single oral dose of amoxicillin (1 g) or of amoxicillin (1 g) plus carbocysteine (300 mg). In the bronchial secretions, at the same plasma concentrations, amoxicillin levels were statistically higher after administration of combined substances. These findings indicate the presence of a pharmacokinetic synergism between these compounds, which allows amoxicillin to penetrate more easily through the hemato-bronchial barrier. The association of amoxicillin and carbocysteine, determining an increase of the quantitative levels of antibiotic in the bronchial secretion (also if it is purulent), performs a sterilizing action in a short time with significant therapeutic advantages.

Aged↗
PubMed1984

Dermorphin, a new peptide from amphibian skin, inhibits the nociceptive thalamic neurons firing rate evoked by noxious stimuli.

Dermorphin is the representative of a new class of potent opioid peptides occurring in amphibian skin and possesses the unique feature of having a D-Ala residue incorporated in the peptide molecule. The effect of dermorphin on the spontaneous and evoked neuronal activity by a nociceptive stimulus was studied in the nucleus lateralis anterior and ventrobasal complex of the rat thalamus. The high firing frequency induced by nociceptive stimuli was blocked when dermorphin was injected intraperitoneally at the dose of 1.5 mg/kg. The action starts about 10 min after injection and lasts on average for 120 min. Naloxone, a specific opioid antagonist, injected i.p. at a dose of 1 mg/kg antagonized the effect of dermorphin. The dermorphin time-course is about twice that of morphine (1.5 mg/kg i.p.) under the same experimental conditions.

Action Potentials↗
PubMed1984

Inhibitory effect of eseroline, an opiate like drug, on the rat nociceptive thalamic neurons activated by peripheral noxious stimuli.

Eseroline is a new agent, derived from physostigmine but lacking in pseudocholinesterase activity, that possesses opioid properties in vivo and in vitro in cats and rodents. The electrophysiological effect of this drug has been investigated. Our findings show that Eseroline (5 mg/kg i.p.), suppresses the nociceptive responses evoked by noxious (mechanical and thermal) stimuli, without affecting the spontaneous firing of neurons in the thalamus of anesthetized rat. This effect starts about 5 min after the administration and lasts on average for about 60 min. Naloxone (1 mg/kg i.p.), injected 10 min before Eseroline, antagonized the antinociceptive action of this drug.

Analgesics, Opioid↗
PubMed1984

Kinetics of penetration and clearance of mezlocillin in the bronchopulmonary tract.

Mezlocillin is an expanded spectrum semisynthetic penicillin for parenteral administration, with a good activity against a wide range of pathogenic bacteria including most anaerobes. The pharmacokinetic parameters of mezlocillin were determined in serum and sputum at the first and the seventh day of treatment with 1 g/im/12 h in patients suffering from bronchopulmonary infections. In a second group of volunteer patients who had to undergo surgery for lung cancer, mezlocillin levels in pulmonary tissue and the corresponding serum levels were determined at different times after drug administration. The data obtained made it possible to obtain information on the penetration and clearance of this drug in the bronchopulmonary tract in comparison with that of the serum. The pharmacokinetic behaviour of mezlocillin ensures an efficient antibacterial action in the respiratory tract.

Bronchi↗
PubMed1983

Pharmacokinetics of Sobrerol in chronic bronchitis. Comparison of serum and bronchial mucus levels.

The pharmacokinetic profile of Sobrerol, a mucolytic drug, has been studied in patients with acute exacerbations of chronic bronchitis and dense sputum. In addition to measurement of serum and urine levels, the concentration in bronchial mucus was also examined, and their correlation was calculated. Mass fragmentographic analysis was used to assay free sobrerol and its principal urinary metabolites hydrated carvone and glucuronidated sobrerol. After the doses and administration routes used, there appeared to be accumulation of sobrerol in bronchial mucus. This is a feature of great interest and value for a drug which has the specific action of liquifying mucus.

Administration, Oral↗
PubMed1983

Activity and tolerability of domifen bromide in patients affected by acute infectious dental diseases: a double-blind placebo-controlled trial.

Thirty-one patients (21 M and 10 F), affected by acute infectious dental disease, were treated with domifen bromide (A) or placebo (Pl). It was found that A had a beneficial effect on the results of clinical controls and reduced the need for the concomitant use of an antibiotic (p = 0.001 and p = .008 respectively). Furthermore, after two days of treatment with A, there was a significant decrease in pain and inflammation (p less than 0.01). A alone or in combination with an antibiotic elicits a good response, improves the prognosis and reduces the number of days of illness.

Acute Disease↗
PubMed1983

Evaluation of domifen bromide in the treatment of acute infectious oral diseases.

By means of a double blind, placebo controlled trial, we have studied 29 patients (14 M and 15 F) affected by different acute infectious oral diseases. Our results suggest that domifen bromide may be useful in treating infectious oral diseases in combination with antibiotics, and in relieving pain and inflammation.

Acute Disease↗
PubMed1983

Cefoperazone pharmacokinetics and sputum levels after single/multiple i.m. injections in bronchopneumopathic patients and bone, pulmonary and prostatic tissue penetration.

Cefoperazone is a third-generation semisynthetic injectable cephalosporin. It has been reported that cefoperazone has beta-lactamase resistance and quite a broad antimicrobial spectrum against many Gram-positive and Gram-negative microorganisms and most anaerobes. In this study, the pharmacokinetics of cefoperazone were examined in a group of 10 patients suffering from acute exacerbations of chronic bronchitis, with purulent or mucopurulent expectorations. Cefoperazone was administered at the dose of 1 g i.m. every 12 hours. Serum and urinary parameters and the profile of bronchial mucus diffusion were assessed after the first administration and during the whole period of treatment which lasted for 7 days. In a second, third, and fourth group of volunteer patients who had to undergo surgical operations, bone, lung and prostatic penetration of cefoperazone was determined in correlation with serum levels.

Bone and Bones↗